Scinai Immunotherapeutics Ltd. stocks have been trading up by 22.16 percent amid strong optimism around its latest biotech developments.
Click Here for a Millionaire's POV on Trading SCNI
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
What Traders Need To Know
- Termination of PinCell PC111 option and license deals shifts the R&D roadmap and may reset near‑term pipeline expectations.
- R&D capital is being redirected into Scinai Immunotherapeutics Ltd.’s in‑house NanoAb antibody platform, tightening focus on proprietary assets.
- Expansion emphasis on the CDMO arm, Scinai Biopharma Services, points toward a stronger services revenue mix.
- Ongoing collaboration with the Max Planck Society and University Medical Center Göttingen supports the scientific base behind NanoAb development.
- Recent move from about $1.66 to $2.04 shows traders quickly repricing SCNI around this strategic pivot.
Weekly Update Sep 07 – Sep 11, 2026: On Saturday, September 12, 2026 Scinai Immunotherapeutics Ltd. stock [NASDAQ: SCNI] is trending up by 22.16%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Healthcare industry expert:
Analyst sentiment – negative
Scinai Immunotherapeutics (SCNI) is a micro-cap, highly speculative biotech with modest revenue of ~$1.31M (revenue/share ~$2.61) and a very low price-to-sales of 0.64, reflecting deep market skepticism. Book value per share of 4.94 versus a price-to-book of 0.34 implies the equity trades at a steep discount to stated net assets, yet this is warranted by extreme value destruction: ROA of -35% and ROE of -169% underscore persistent, severe unprofitability.
The balance sheet shows total assets of $11.6M and equity of $8.1M, with leverage ratio 4.7 and long-term debt/capital at 0.19, indicating moderate financial leverage but limited flexibility for prolonged cash burn. Retained earnings of -$125.8M highlight a long history of losses, partially masked by $130M of additional paid-in capital and $5.6M preferred stock. Cash of $1.66M, working capital of $0.47M, and only 31 employees emphasize a thinly capitalized, small-scale operation highly dependent on external funding.
Technically, SCNI has shifted from a flat micro-range (1.66–1.71) into a sharp breakout, with the latest weekly bar opening 1.66 and closing 2.04 after a spike high of 2.22. This impulsive move, likely on elevated volume, defines 1.65–1.70 as new support and 2.20–2.25 as immediate resistance. The dominant trend is now short-term bullish; an actionable trading level is a pullback buy near 1.75–1.80 with a tight stop below 1.60.
More Breaking News
- UiPath (PATH) Stock Faces Cautious Wall Street As AI Push Accelerates
- UTHR Stock Jumps As Tyvaso Win And Massive Buyback Fuel Momentum
- Accenture Stock Jumps As AI Deals And New Units Fuel Momentum
- QSI Stock Pops As Proteus Platform Outperforms And Roadshow Expands
The decision to terminate the PinCell PC111 option and concentrate R&D on the in-house NanoAb platform, alongside scaling CDMO activities at Scinai Biopharma Services, reduces pipeline breadth but improves capital focus and potential near-term service revenue. Relative to healthcare and biotech benchmarks, SCNI remains far riskier, illiquid, and more execution-dependent. Near term, upside is capped by dilution risk and weak fundamentals; fair trading range is $1.60–2.50, with support at $1.60 and resistance at $2.50.
Quick Financial Overview
Scinai Immunotherapeutics Ltd. is trading more like a deep value, high‑risk biotech than a steady growth story. With revenue around $1.31M and a price‑to‑sales ratio near 0.64, the market is not paying a rich multiple for SCNI. Book value per share sits close to 4.94 while the stock trades far below that, reflected in a price‑to‑book ratio of about 0.34. On paper, there is a wide gap between market price and stated equity value.
The flip side is clear in the efficiency and return figures. Return on assets around -35% and return on equity near -169% show that capital has not yet translated into profitable activity. The balance sheet lists roughly $11.63M in total assets and $8.10M in equity, backed by about $1.66M in cash. Leverage is material, with a ratio of 4.7 and roughly $1.94M in long‑term debt and lease obligations, so SCNI is not a low‑risk balance sheet.
On the chart, SCNI traded flat and tight near $1.66–$1.71 before a sharp push to a $2.22 weekly high and a $2.04 close. That is a clean breakout from the recent range and shows aggressive buying interest around the strategic news. Intraday, a 5‑minute candle with a $1.651 low and $1.7802 high and close at $1.66 confirms earlier volatility and liquidity, giving traders clear reference levels. The former range near $1.65–$1.70 now acts as a key support zone, while $2.22 becomes the first resistance to watch.
Conclusion
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.